US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non–Small-Cell Lung Cancer
Journal of Clinical Oncology · 2023
DOI: 10.1200/jco.22.02509 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2023. Verfasst von Oladimeji Akinboro und 13 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE On March 4, 2022, the US Food and Drug Administration (FDA) approved nivolumab plus platinum-doublet chemotherapy for the neoadjuvant treatment of patients with resectable non–small-cell lung cancer (NSCLC). We discuss the FDA's review of the key data and regulatory considerations supporting this approval. PATIENTS AND METHODS The approval was based on the results of CheckMate 816, an international, multiregional, active-controlled trial that randomly assigned 358 patients with resectable NSCLC, stage IB (≥4 cm) to IIIA (N2) per the American Joint Committee on Cancer seventh staging edition to receive either nivolumab plus platinum-doublet or platinum-doublet chemotherapy alone for three cycles before planned surgical resection. The major efficacy end point that supported this approval was event-free survival (EFS). RESULTS At the first planned interim analysis (IA), the hazard ratio (HR) for EFS was 0.63 (95% CI, 0.45 to 0.87; P = .0052; statistical significance boundary = .0262) favoring the nivolumab plus chemotherapy arm; the median EFS was 31.6 months (95% CI, 30.2 to not reached) in the nivolumab plus chemotherapy arm versus 20.8 months (95% CI, 14.0 to 26.7) in the chemotherapy-only arm. At the time of a prespecified IA for overall survival (OS), 26% of patients had died, and the HR for OS was 0.57 (95% CI, 0.38 to 0.87; P = .0079; statistical significance boundary = .0033). Eighty-three percent of patients in the nivolumab-containing arm versus 75% in the chemotherapy-only arm received definitive surgery. CONCLUSION This approval, the first for any regimen for the neoadjuvant treatment of NSCLC in the United States, was supported by a statistically significant and clinically meaningful improvement in EFS with no evidence of detriment in OS or negative impact on patients' receipt and timing of surgery or surgical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD.
- Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD.
ORCID-Profile: Oladimeji Akinboro, Bronwyn Mixter, Shenghui Tang, Richard Pazdur
Zitieren
APA
Akinboro, O., Drezner, N., Amatya, A., Runyan, J., Fourie-Zirkelbach, J., Zhao, M., Bi, Y., Korsah, K., Mixter, B., Tang, S., Larkins, E., Pazdur, R., Beaver, J. A., & Singh, H. (2023). US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.22.02509
Vancouver
Akinboro O, Drezner N, Amatya A, Runyan J, Fourie-Zirkelbach J, Zhao M, et al. US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 2023. doi:10.1200/jco.22.02509
BibTeX
@article{Akinboro2023,
author = {Akinboro, Oladimeji and Drezner, Nicole and Amatya, Anup and Runyan, Jin and Fourie-Zirkelbach, Jeanne and Zhao, Miao and Bi, Youwei and Korsah, Kwadwo and Mixter, Bronwyn and Tang, Shenghui and Larkins, Erin and Pazdur, Richard and Beaver, Julia A and Singh, Harpreet},
title = {US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non–Small-Cell Lung Cancer},
journal = {Journal of Clinical Oncology},
year = {2023},
doi = {10.1200/jco.22.02509}
}
EUVIMED